Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Kymriah® (tisagenlecleucel) – New indication
May 28, 2022 - Novartis announced the FDA approval of Kymriah (tisagenlecleucel), for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
